147 related articles for article (PubMed ID: 11717804)
1. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
2. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
3. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
5. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
6. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides.
Luo Z; Zhou N; Luo J; Hall JW; Huang Z
Biochem Biophys Res Commun; 1999 Oct; 263(3):691-5. PubMed ID: 10512741
[TBL] [Abstract][Full Text] [Related]
7. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand.
Dong CZ; Kumar S; Choi WT; Madani N; Tian S; An J; Sodroski JG; Huang Z
J Med Chem; 2005 Dec; 48(25):7923-4. PubMed ID: 16335916
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles.
DeMarco SJ; Henze H; Lederer A; Moehle K; Mukherjee R; Romagnoli B; Robinson JA; Brianza F; Gombert FO; Lociuro S; Ludin C; Vrijbloed JW; Zumbrunn J; Obrecht JP; Obrecht D; Brondani V; Hamy F; Klimkait T
Bioorg Med Chem; 2006 Dec; 14(24):8396-404. PubMed ID: 17010618
[TBL] [Abstract][Full Text] [Related]
9. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
10. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.
Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C
J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
12. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
13. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
[TBL] [Abstract][Full Text] [Related]
15. Targeting HIV-1 through molecular modeling and docking studies of CXCR4: leads for therapeutic development.
Singh S; Malik BK; Sharma DK
Chem Biol Drug Des; 2007 Mar; 69(3):191-203. PubMed ID: 17441905
[TBL] [Abstract][Full Text] [Related]
16. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
17. SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development.
Kumar S; Choi WT; Dong CZ; Madani N; Tian S; Liu D; Wang Y; Pesavento J; Wang J; Fan X; Yuan J; Fritzsche WR; An J; Sodroski JG; Richman DD; Huang Z
Chem Biol; 2006 Jan; 13(1):69-79. PubMed ID: 16426973
[TBL] [Abstract][Full Text] [Related]
18. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists.
Våbenø J; Nikiforovich GV; Marshall GR
Biopolymers; 2006; 84(5):459-71. PubMed ID: 16552740
[TBL] [Abstract][Full Text] [Related]
19. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
